STUDY OF RESISTANCE FOR RECENTLY MARKETED CARBAPENEM DRUG AMONG HOSPITALISED PATIENTS IN SANA'A, YEMEN

  • Ali Alyahawi Depatment of Pharmacy, Al-Razi University, Yemen
  • Ali Alkaf Faculty of Pharmacy, Sana'a University, Yemen.
  • Rashad Alnamer Faculty of Pharmacy, Thamar University, Yemen.
  • Taha Alnosary Faculty of Medical Sciences, The National University, Yemen.

Abstract

Carbapenem resistance is a major and a future public health problem globally. It occurs mainly among Gram-negative bacteria.  Meropenem is the recently marketed carbapenem drug in Yemen. However, recent emergence of carbapenem-resistant isolates has become a major healthcare concern. The current study was designed to estimate the prevalence of meropenem resistance among hospitalised patients in Sana'a, Yemen. The study was performed at a local hospital in Sana’a, Yemen. The records of Meropenem susceptibility were taken for hospitalised patients. A total of 443 Meropenem susceptibility samples were collected from August, 2017 to July, 2018. The meropenem susceptibility was studied against several isolated pathogens. Out of 443 study sample, 316 (71.3%) were meropenem sensitive isolates and 25.3% of samples were resistant. The Escherichia coli isolates were observed in 27.5% of sample, followed by Pseudomonas aeruginosa (19.6%). 36.4% of total meropenem sensitive isolates (115/316) were Escherichia coli. In addition, 94.3% (115/122) of Escherichia coli isolates were meropenem sensitive. However, the Klebsiella species had higher meropenem resistance than other pathogens (30/112; 26.8%). Moreover, 89.7% (26/29) of Acinetobacter species isolates were meropenem resistant. 82.4% (42/51) of Klebsiella pneumonia isolates were meropenem sensitive and 32.2% (28/87) of Pseudomonas aeruginosa were meropenem resistance. In the present study, 34.5% (109/316) of meropenem sensitive isolates were from blood cultures, followed by sputum cultures (23.7%; 75/316). However, 58% (65/112) of sputum culture isolates were meropenem resistance. This study concluded that the percentage of resistance to meropenem was high (25.3%) and cannot be neglected. Continued surveillance to closely monitor trends as well as infection control and antibiotic stewardship activities are necessary to preserve treatment options. A more careful monitoring for use of broad-spectrum antibiotics should be instituted.


Peer Review History:


UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.


Received file


pdf3.JPG


Average Peer review marks at initial stage: 4.5/10


Average Peer review marks at publication stage: 7.0/10


Reviewer(s) detail:


Name: Prof. Dr. Hüsniye Kayalar  


  Affiliation: Ege University, Turkey


E-mail: husniyekayalar@gmail.com


 


Name: Noha El Baghdady 


Affiliation: MTI University, Cairo, Egypt


E-mail: nohasalah21@yahoo.com


Comments of reviewer(s):


pdf3.JPG

Keywords: Meropenem, prevalence, resistance
Statistics
116 Views | 142 Downloads
How to Cite
Alyahawi, A., A. Alkaf, R. Alnamer, and T. Alnosary. “STUDY OF RESISTANCE FOR RECENTLY MARKETED CARBAPENEM DRUG AMONG HOSPITALISED PATIENTS IN SANA’A, YEMEN”. Universal Journal of Pharmaceutical Research, Vol. 3, no. 5, Nov. 2018, doi:https://doi.org/10.22270/ujpr.v3i5.203.
Section
Research Articles